Pandraklakis Anastasios, Haidopoulos Dimitrios, Lappas Theodoros, Stamatakis Emmanouil, Oikonomou Maria D, Valsamidis Dimitrios, Rodolakis Alexandros, Thomakos Nikolaos
Division of Gynaecologic Oncology, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, GRC.
Department of Anaesthesiology, Alexandra General Hospital, Athens, GRC.
Cureus. 2023 Jun 15;15(6):e40453. doi: 10.7759/cureus.40453. eCollection 2023 Jun.
Objective The aim of this study is to present our experience and evaluate the safety and outcomes of the implementation of Enhanced Recovery After Surgery (ERAS) protocols in obese patients who underwent surgery for suspected or confirmed gynecological malignancies. Method From January 2020 to September 2021, 217 patients underwent laparotomy for a confirmed or suspected gynecological malignancy following a 19-element ERAS pathway. The patients were divided into two groups: obese (BMI ≥ 30 kg/m, n = 104) and non-obese (BMI < 30, n = 113). Both groups were treated with a 19-element ERAS protocol. Results After dividing the 217 patients into two groups, significantly more comorbidities were observed in the obese group (diabetes mellitus: 23% vs. 8%, p = 0.004; ASA score grade 3: 25.0% vs. 6.2%, p < 0.001), as well as higher rates of endometrial cancer (51.9% vs. 17.7%, p < 0.001) compared to the non-obese group. The overall ERAS compliance rates when matched element by element were similar. Postoperatively, complication rates of all grades were significantly higher in the obese group (46.1% vs. 27.4%, p < 0.001) without differences in the length of stay, readmission, and reoperation rates. Conclusion In this retrospective study, we showed that obese gynecological oncology patients can be safely managed with ERAS protocols perioperatively while potentially minimizing the adverse outcomes in these otherwise high-risk patients.
目的 本研究旨在分享我们的经验,并评估在疑似或确诊为妇科恶性肿瘤的肥胖患者中实施加速康复外科(ERAS)方案的安全性和效果。方法 2020年1月至2021年9月,217例患者按照19项ERAS路径接受了确诊或疑似妇科恶性肿瘤的剖腹手术。患者分为两组:肥胖组(BMI≥30 kg/m²,n = 104)和非肥胖组(BMI < 30,n = 113)。两组均采用19项ERAS方案治疗。结果 将217例患者分为两组后,肥胖组的合并症明显更多(糖尿病:23% 对8%,p = 0.004;美国麻醉医师协会(ASA)评分3级:25.0% 对6.2%,p < 0.001),与非肥胖组相比,子宫内膜癌的发生率也更高(51.9% 对17.7%,p < 0.001)。逐项匹配时,总体ERAS依从率相似。术后,肥胖组所有级别的并发症发生率显著更高(46.1% 对27.4%,p < 0.001),但住院时间、再入院率和再次手术率无差异。结论 在这项回顾性研究中,我们表明肥胖的妇科肿瘤患者围手术期可通过ERAS方案安全管理,同时可能将这些原本高危患者的不良结局降至最低。